High Court Turns Away CRISPR Patent Validity Dispute
The U.S. Supreme Court on Monday rejected Agilent Technologies' bid to revive patents on the gene-editing tool CRISPR, which centers on the burden of proof in establishing prior art....To view the full article, register now.
Already a subscriber? Click here to view full article